(Aurora, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”), a biopharmaceutical company developing
drug candidates for the prevention and treatment of cancer, today announced that the first patient has been
enrolled and first dose administered in its ongoing Phase I/II clinical safety, tolerability and preliminary
efficacy study of L-DOS47 in Poland.